The Preferred Phosphate Binder in Dialysis Patients

Lowrie E.G. , Lew N.L. Death risk in hemodialysis patients: the predictive value of commonly measured variables and evaluation of death rate differences between facilities. Am J Kidney Dis 1990; 15: 458–82.

Block G.A. , Hulbert–Shearon T.E. , Levin N.W. , Port F.K. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607–17.

Delmez J. , Slatopolsky E. Hyperphosphatemia: its consequences and treatment in patients with chronic renal disease. Am J Kidney Dis 1992; 4: 303–17.

Rostand S.G. , Sanders C. , Kirk K. , Rutsky E.A. , Fraser R.G. Myocardial calcification and cardiac dysfunction in chronic renal failure. Am J Med 1988; 85: 651–7.

Braun J. , Oldendorf M. , Moshage W. , Heidler R. , Zeitler E. , Luft F.C. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 1996; 27: 394–401.

Ribeiro S. , Ramos A. , Brandao A. , Rebelo J.R. , Guerra A. , Resina C. Cardiac valve calcification in hemodialysis patients: the role of calcium–phosphate metabolism. Nephrol Dial Transplant 1998; 13: 2037–40.

Huting J. Mitral valve calcification as an index of left ventricular dysfunction in patients with end-stage renal disease on peritoneal dialysis. Chest 1994; 105: 383–8.

Slatopolsky E. , Delmez J. Pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis 1994; 23: 229–36.

Almaden Y. , Canalejo A. , Hernandez A. Direct effect of phosphorus on PTH secretion from whole rat parathyroid glands in vitro. J Bone Miner Res 1996; 11: 970–6.

Denda M. , Finch J. , Slatopolsky E. Phosphorus accelerates the development of parathyroid hyperplasia and secondary hyperparathyroidism in rats with renal failure. Am J Kidney Dis 1996; 28: 596–602.

Slatopolsky E. , Finch J. , Denda M. Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro. J Clin Invest 1996; 97: 2534–40.

Llach F. Secondary hyperparathyroidism in renal failure: the trade-off hypothesis revisited. Am J Kidney Dis 1995; 25: 663–79.

Chertow G.M. , Martin K.J. Current and future therapies for the medical management of secondary hyperparathyroidism. Semin Dial 1998; 11: 267–70.

Combe C. , Aparicio M. Phosphorus and protein restriction and parathyroid function in chronic renal failure. Kidney Int 1994; 46: 1381–6.

Salusky I.B. , Foley J. , Nelson P. , Goodman D.G. Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease. N Engl J Med 1991; 324: 527–31.

Sheikh M.S. , Maguire J.A. , Emmett M. , Santa Ana C.A. , Nicar M.J. , Schiller L.R. Reduction of dietary phosphorus by phosphorus binders. A theoretical, in vitro, and in vivo study. J Clin Invest 1989; 83: 66–73.

Schiller L.R. , Santa Ana C.A. , Sheikh M.S. , Emmett M. , Fordtran J.S. Effect of the time of administration of calcium acetate on phosphorus binding. N Engl J Med 1989; 320: 1110–13.

Slatopolsky E. , Weerts C. , Lopez–Hiker S. , Norwood K. , Giles K. , Fryer P. Long-term effects of calcium carbonate and 2.5 mEq/liter calcium dialysate on mineral metabolism. Kidney Int 1989; 36: 897–903.

Mai M.L. , Emmett M. , Sheikh M.S. , Santa Ana C.A. , Schiller L.R. , Fordtran J.S. Calcium acetate, an effective phosphorus binder in patients with renal failure. Kidney Int 1989; 36: 690–5.

Fournier A. , Moriniere P. , Sebert J.L. , Dhissi H. , Atik A. , Leflon P. Calcium carbonate, an aluminum free agent for control of hyperphosphatemia, hypocalcemia and hyperparathyroidism. Kidney Int 1986; 29(Suppl): S114–19.

Schaefer K. , Scheer J. , Asmus G. , Umlauf E. , Hagemann J. , von Herrath D. The treatment of uraemic hyperphosphataemia with calcium acetate and calcium carbonate: a comparative study. Nephrol Dial Transplant 1991; 6: 170–5.

Merchant M.R. , Hutchison A.J. , Butler S.J. , Boulton H. , Hinchcliffe R. , Gokal R. Calcium, magnesium mass transfer and lactate balance study in CAPD patients with reduced calcium/magnesium and high lactate dialysis fluid. In: Khanna R. , Nolph K.D. , Prowant B.F. , Twardowski Z.J. , Oreopoulos D.G. , eds. Advances in peritoneal dialysis. Toronto: Peritoneal Dialysis Bulletin, 1992; 8: 365–8.

Banalagay E.E. , Bernardini J. , Piraino B. Calcium mass transfer with 10-hour dwell time using 1.25 versus 1.75 mmol/L calcium dialysate. In: Khanna R. , Nolph K.D. , Prowant B.F. , Twardowski Z.J. , Oreopoulos D.G. , eds. Advances in peritoneal dialysis. Toronto: Peritoneal Dialysis Publications, 1993; 9: 271–3.

Ritz E. , Passlick–Deetjen J. , Zeier M. , Stefanski A. Prescription of calcium concentration and PTH control. Perit Dial Int 1996; 16(Suppl 1): S300–4.

Armstrong A. , Beer J. , Noonan K. , Cunningham J. Reduced calcium dialysate in CAPD patients: efficacy and limitations. Nephrol Dial Transplant 1997; 12: 1223–8.

Chagnac A. , Ori Y. , Weinstein T. , Herman M. , Korzets A. , Zevin D. Calcium balance during pulse alfacalcidol therapy for secondary hyperparathyroidism in CAPD patients treated with 1.0 and 1.25 mmol/L dialysate calcium. Am J Kidney Dis 1999; 33: 82–6.

Hutchison A. , Gokal R. Improved solutions for peritoneal dialysis: physiological calcium solutions, osmotic agents and buffers. Kidney Int 1992; 42(Suppl 38): S153–9.

Cunningham J. , Beer J. , Coldwell R. , Noonan K. , Sawyer N. , Makin H. Dialysate calcium reduction in CAPD patients treated with calcium carbonate and alfacalcidol. Nephrol Dial Transplant 1992; 7: 63–8.

Passlick J. , Wilhem M. , Busch T. , Grabensee B. , Ohnesorge F.K. Calcium alginate, an aluminum-free phosphate binder in patients on CAPD. Clin Nephrol 1989; 32: 96–100.

Parsons V. , Baldwin D. , Moniz C. , Marsden J. , Ball E. , Rifkin I. Successful control of hyperparathyroidism in patients on CAPD using magnesium carbonate and calcium carbonate as phosphate binders. Nephron 1993; 63: 379–83.

Moriniere P. , Vinatier I. , Westeel P.F. , Cohemsolal M. , Belbrik S. , Abdulmassih Z. Magnesium hydroxide as complementary aluminium-free phosphate binder to moderate doses of oral calcium in uraemic patients on chronic haemodialysis: lack of deleterious effect on bone mineralisation. Nephrol Dial Transplant 1988; 3: 651–6.

Zimmerman E. , Wassmer S. , Steudle V. Long-term treatment with calcium-alpha-ketoglutarate corrects secondary hyperparathyroidism. Miner Electrolyte Metab 1996; 22: 119–22.

Bro S. , Rasmussen R.A. , Handberg J. , Olgaard K. , Feldt– Rasmussen B. Randomized crossover study comparing the phosphate-binding efficacy of calcium ketoglutarate versus calcium carbonate in patients on chronic hemodialysis. Am J Kidney Dis 1998; 32: 257–62.

Birck R. , Zimmermann E. , Wassmer S. , Nowack R. , van der Woude F.J. Calcium ketoglutarate versus calcium acetate for the treatment of hyperphosphataemia in patients on maintenance haemodialysis: a cross over study. Nephrol Dial Transplant 1999; 14: 1475–9.

Chertow G.M. , Burke S.K. , Lazarus J.M. , Stenzel K.M. , Wombolt D. , Goldberg D. Poly[allylamine hydro-chloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperparathyroidism in chronic renal failure. Am J Kidney Dis 1997; 29: 66–71.

Slatopolsky E. , Burke S.K. , Dillon MA , and the RenaGel Study Group. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. Kidney Int 1999; 55: 299–307.

Wilkes B.M. , Reiner D. , Kern M. , Burke S. Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (RenaGel) in dialysis patients. Clin Nephrol 1998; 50: 381–6.

Bleyer A.J. , Burke S.K. , Dillon M. , Garrett B. , Kant K.S. , Lynch D. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 1999; 33: 694–701.

Hergesell O. , Ritz E. Stabilized polynuclear iron hydroxide is an efficient oral phosphate binder in uraemic patients. Nephrol Dial Transplant 1999; 14: 863–7.

Chang J.M. , Hwang S.J. , Tsai J.C. Effect of ferric poly-maltose as a phosphate binder in hemodialysis patients. Nephrol Dial Transplant 1999; (in press).

Spengler K. , Follman H. , Boos K-S Cross-linked iron dextran is an efficient oral phosphate binder in the rat. Nephrol Dial Transplant 1996; 11: 808–12.

Dewberry K. , Fox J.S. , Stewart J. , Murray J.R. , Hutchison A.J. Lanthanum carbonate: a novel non-calcium containing phosphate binder (Abstract). J Am Soc Nephrol 1997; 8: 560A.